Identification of hemoglobin-α and -β subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer

Cancer Science

Volumn 96, Issue 3, 2005, Pages 197-201

  Woong Shick, Ahn ^a   Sung Pil, Park ^b   Su Mi, Bae ^c   Joon Mo, Lee ^a   Sung Eun, Namkoong ^a   Gye Hyun, Nam ^d   Young Lae, Cho ^e   Ho Sun, Choi ^f   Heung Jae, Jun ^c   Chong Kook, Kim ^g   Young Wan, Kim ^c   Byoung Don, Han ^b   Hyun Sun, Jin ^c  

^a The Catholic University of Korea   (South Korea)

^b Korea Telecom Research Cent   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Soonchunhyang University   (South Korea)

^e Res Inst for Phys Educ Sport S Kyung Pook University   (South Korea)

^f Chonnam National University Medical School   (South Korea)

^g Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN ALPHA CHAIN; HEMOGLOBIN BETA CHAIN;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN PURIFICATION; SENSITIVITY ANALYSIS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOGLOBIN A; HUMANS; MASS SPECTROMETRY; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; PROTEIN ARRAY ANALYSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 20244373047     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2005.00029.x     Document Type: Article

References (28)

1. Korea National Cancer center. Korea Cancer Registry, 2002.
2. Menon U, Jacobs IJ. Recent developments in ovarian cancer screening. Curr Opin Obstet Gynecol 2000; 12: 39-42.
3. Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, Reddy ST, Farias-Eisner R. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips. Potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 2003; 100: 12343-8.
4. Ahmed N, Riley C, Oliva K, Stutt E, Rice GE, Quinn MA. Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid. J Pathol 2003; 201: 229-37.
5. Freitas S, Moore DH, Michael H, Kelley MR. Studies of apurinic/apyrimidinic endonuclease/ref-1 expression in epithelial ovarian cancer: correlations with tumor progression and platinum resistance. Clin Cancer Res 2003; 9: 4689-94.
6. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287: 1671-9.
7. Tonin PN, Hudson TJ, Rodier F, Bossolasco M, Lee PD, Novak J, Manderson EN, Provencher D, Mes-Masson AM. Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene 2001; 20: 6617-26.
8. Yoon JH, Lee JM, Namkoong SE, Kim JH, Kim CK, Lee YJ, Kim YW, Ahn WS. CDNA Microarray analysis of gene expression profiles associate with cervical cancer. Cancer Res Treat 2003; 35: 451-9.
9. Schrader M, Schulz-Knappe P. Peptidomics technologies for human body fluids. Trends Biotechnol 2001; 19: S55-60.
10. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-7.
11. Petricoin EF, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K, Simone CB, Levine PJ, Linehan WM, Emmert-Buck MR, Steinberg SM, Kohn EC, Liotta LA. Serum proteomics patterns for detection of prostate cancer. J Natl Cancer Inst 2002; 94: 1576-8.
12. Rogers MA, Clarke P, Noble J, Munro NP, Paul A, Selby PJ, Banks RE. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res 2003; 63: 6971-83.
13. Shiwa M, Nishimura Y, Wakatabe R, Fukawa A, Arikuni H, Ota H, Kato Y, Yamori T. Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. Biochem Biophys Res Commun 2003; 309: 18-25.
14. Ye B, Cramer DW, Skates SJ, Gygi SP, Pratomo V, Fu L, Horick NK, Licklider LJ, Schorge JO, Berkowitz RS, Mok SC. Haptoglobin-a subunit as potential serum biomarker in ovarian cancer: Identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 2003; 9: 2904-11.
15. Zhang L, Yu W, He T, Yu J, Caffrey RE, Dalmasso EA, Fu S, Pham T, Mei J, Ho JJ, Zhang W, Lopez P, Ho DD. Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 2002; 298: 995-1000.
16. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. Gene ontology. tool for the unification of biology. Nat Genet 2000; 25: 25-9.
17. Doniger SW, Salomonis N, Dahlquist KD, Vranizan K, Lawlor SC, Conklin BR. MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data. Genome Biol 2003; 4: R7-12.
18. Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, Kennedy AW, Belinson J, Markman M, Casey G. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998; 280: 719-23.
19. Tuxen MK, Soletormos G, Petersen PH, Schioler V, Dombernowsky P. Assessment of biological variation and analytical imprecision of CA 125, CEA, and TPA in relation to monitoring of ovarian cancer. Gynecol Oncol 1999; 74: 12-22.
20. Luo LY, Katsaros D, Scorilas A, Fracchioli S, Piccinno R, Rigault de la Longrais IA, Howarth DJ, Diamandis EP. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin Cancer Res 2001; 7: 2372-9.
21. Negishi Y, Iwabuchi H, Sakunaga H, Sakamoto M, Okabe K, Sato H, Asano G. Serum and tissue measurements of CA72-4 in ovarian cancer patients. Gynecol Oncol 1993; 48: 148-54.
22. Christoph SK, Tilman V, Edeltraud K, Horst A, Kurt Z, Karl P, Gunther RA. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 2001; 1: 890-8.
23. Bottini A, Berruti A, Brizzi MP, Bersiga A, Generati D, Allevi G, Aguggini S, Bolsi G, Bonardi S, Bertoli G, Alquati P, Dogliotti L. Pretreatment hemoglobin levels significantly predict the tumor response to primary chemotherapy in human breast cancer. Br J Cancer 2003; 89: 977-92.
24. Glaser CM, Millesi W, Kornek GV, Lang S, Schull B, Watzinger F, Selzer E, Lavey RS. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001; 50: 705-15.
25. Kovacs R, Wilhelm R, Heinrichsohn D. Survival of exclusively irradiated patients with NSCLC. Significance of pretherapeutic hemoglobin levels. Strahlenther Onkol 1998; 174: 128-32.
26. Bast RC Jr, Urban N, Shridhar V, Smith D, Zhang Z, Skates S, Lu K, Liu J, Fishman D, Mills G. Early detection of ovarian cancer: promise and reality. Cancer Treat Res 2002; 107: 61-97.
27. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48: 1296-304.
28. Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, Nasim S, Wright Jr. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urinE. Am J Pathol 2001; 158: 1491-502.